Strategic partnerships Curida has recently formed a strategic partnership with Rommelag, a global leader in Blow-Fill-Seal (BFS) technology, signaling potential for expanded BFS based collaborations and preferred supplier status for teams seeking integrated BFS sterile filling capabilities.

Eco credentials Eco awards recognition (EcoVadis Bronze) enhances Curida’s sustainability profile, offering a selling point to pharma partners with ESG mandates and carbon footprint reduction goals.

European CDMO focus As a Norway-based CDMO with sterile and aseptic liquid manufacturing expertise (BFS and nasal spray), Curida is positioned to attract international pharma companies seeking European manufacturing capacity, flexible collaboration models, and potential for nearshoring.

Growth investment Recent growth investments from Signet Healthcare Partners and existing shareholders indicate strong capital support and potential for capacity expansion, enabling scaled manufacturing programs for mid-size to large biotech and pharma clients.

Market positioning Curida serves a broad client base from small biotech to Big Pharma with a lean, flexible organization, presenting opportunities to upsell additional development and manufacturing services across the product lifecycle, including development, fill-finish, and nasal delivery systems.